Search

Your search keyword '"van Engelen K."' showing total 115 results

Search Constraints

Start Over You searched for: Author "van Engelen K." Remove constraint Author: "van Engelen K."
115 results on '"van Engelen K."'

Search Results

1. Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families

3. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

4. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy

6. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

10. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

11. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.

12. Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study

14. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

15. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

16. Erratum: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers (Breast Cancer Res (2020) 22 (8) DOI: 10.1186/s13058-020-1247-4).

17. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers.

18. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes.

19. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers (vol 22, 8, 2020)

20. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

21. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

22. Cancer risks for other sites in addition to breast in CHEK2c.1100delC families

23. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.

24. Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

25. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

26. Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer

27. Patterns of co-occurrence of congenital heart defects follows distinct patterns

28. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study

29. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations

30. Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study

31. The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations

32. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

33. Genetics and inheritance issues in congenital heart disease

35. Genome-wide association study identifies loci on 12q24 and 13q32 associated with Tetralogy of Fallot

36. Ebstein’s anomaly may be caused by mutations in the sarcomere protein gene MYH7

37. The Authors' reply

40. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

41. Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers

42. Late-onset tumors in rhabdoid tumor predisposition syndrome type-1 (RTPS1) and implications for surveillance.

43. Cohort profile: a nationwide study in Dutch CHEK2 c.1100delC families using the infrastructure of the HEreditary Breast and Ovarian cancer study Netherlands - Hebon-CHEK2.

44. From Alpha-Thalassemia Trait to NPRL3 -Related Epilepsy: A Genomic Diagnostic Odyssey.

45. Urinary incontinence more than 15 years after premenopausal risk-reducing salpingo-oophorectomy: a multicentre cross-sectional study.

46. SLC6A1 variant pathogenicity, molecular function and phenotype: a genetic and clinical analysis.

47. Performance of the eHealth decision support tool, MIPOGG, for recognising children with Li-Fraumeni, DICER1, Constitutional mismatch repair deficiency and Gorlin syndromes.

48. Germline whole genome sequencing in adults with multiple primary tumors.

49. Long-term effects of premenopausal risk-reducing salpingo-oophorectomy on cognition in women with high familial risk of ovarian cancer: A cross-sectional study.

50. High-Grade Serous Carcinoma at Risk-Reducing Salpingo-Oophorectomy in Asymptomatic Carriers of BRCA1/2 Pathogenic Variants: Prevalence and Clinical Factors.

Catalog

Books, media, physical & digital resources